Advances in Vaccines and Antimicrobial Therapy—2nd Edition

Topic Information

Dear Colleagues,

This topic is a second edition of “Advances in Vaccines and Antimicrobial Therapy”. Our first edition has published 20 papers with a total of 37474 views. You can read the latest papers at: https://www.mdpi.com/topics/X66IH7XM49. Now we have set up a second edition and look forward to receiving more submissions.

The fields of prevention and treatment of infectious diseases have been gaining momentum after the outbreak of the coronavirus pandemic, with several advances both in vaccine technology and in the development of new antimicrobials. The usefulness of monoclonal antibodies has been tested, along with several old and new compounds with antiviral activity, but the search for new avenues, combining diverse strategies and reexamining older drugs for potential new activities, is quickly evolving. Interactions of drugs with the local microbiota, combinations of systemic approaches, targeting immune defense mechanisms together with arresting microbial host invasion, refinements in nano-formulations, drug delivery, rapid genotyping of microorganisms, and engineering of bacteriophages in the fight against multidrug resistance are just some of the areas in which breakthrough research is expected to bring significant advances in the near future.

The aim of this Topic is to offer an updated view of the advances in all the fields of antimicrobial therapy and prevention. This Topic collection invites contributions of research articles, reviews, and meta-analyses, exploring the new horizons of antimicrobial therapy and vaccine development. Both in vitro and in vivo studies, field studies, and reports, as well as bold new hypotheses based on original observations, are also welcome. We, as Editors, expect both academic research institutions and industry research to be represented in this collection on issues of primary relevance for health systems and individual safety in the near future.

Dr. Raffaele D’Amelio
Dr. Roberto Paganelli
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Biomolecules biomolecules	4.8	9.2	2011	19.4 Days	CHF 2700	Submit
Cells cells	5.2	10.5	2012	16 Days	CHF 2700	Submit
International Journal of Molecular Sciences ijms	4.9	9.0	2000	20.5 Days	CHF 2900	Submit
Parasitologia parasitologia	1.5	2.4	2021	18.5 Days	CHF 1200	Submit
Pathogens pathogens	3.3	6.8	2012	13.5 Days	CHF 2200	Submit
Vaccines vaccines	3.4	9.9	2013	19.6 Days	CHF 2700	Submit
Biologics biologics	-	7.2	2021	23.5 Days	CHF 1200	Submit
Microorganisms microorganisms	4.2	7.7	2013	15.2 Days	CHF 2700	Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Related Topic

Published Papers (1 paper)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All Biomolecules Cells IJMS Parasitologia Pathogens Vaccines Biologics Microorganisms

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

attachment

Supplementary material:
Supplementary File 1 (ZIP, 79 KiB)

12 pages, 439 KiB  

Open AccessArticle

A Single-Center Retrospective Study on Early Treatment for COVID-19 in Solid Organ Transplant Recipients During the Omicron Era: Outcomes and SARS-CoV-2 Viral Kinetics

by Eugenia Milozzi, Elisa Biliotti, Alessandro Caioli, Valentina Mazzotta, Laura Loiacono, Silvia Meschi, Alessia Rianda, Andrea Antinori, Fabrizio Maggi and Gianpiero D’Offizi

Microorganisms 2025, 13(8), 1872; https://doi.org/10.3390/microorganisms13081872 - 11 Aug 2025

Viewed by 172

Abstract

Solid organ transplant recipients (SOTRs) are at high risk of severe coronavirus disease 2019 (COVID-19), therefore early treatment of mild infections is crucial to prevent increased morbidity and mortality. The effectiveness of early treatment in SOTRs has yet to be fully characterized due [...] Read more.

Solid organ transplant recipients (SOTRs) are at high risk of severe coronavirus disease 2019 (COVID-19), therefore early treatment of mild infections is crucial to prevent increased morbidity and mortality. The effectiveness of early treatment in SOTRs has yet to be fully characterized due to the emergence of new SARS-CoV-2 variants and to COVID-19 vaccination implementation. The aim of this single-center retrospective study is to evaluate the outcomes, safety and impact on SARS-CoV-2 viral load kinetics of COVID-19 early treatment in SOTRs. The study includes 80 SOTRs with a laboratory-confirmed diagnosis of symptomatic SARS-CoV-2 infection enrolled between January and October 2022 and treated with either monoclonal antibodies or antivirals. All patients received COVID-19 vaccination and 68.8% of them showed detectable levels of anti-spike (S) antibodies. The occurrence of clinical events (hospitalization, intensive care unit admission, or death) was assessed within 30 days after treatment initiation. The quantification of SARS-CoV-2 viral load were performed at baseline and at day-7. The rate of hospitalization was 2.5% [0.3–9%] and no deaths occurred. All patients completed treatment with no serious adverse events. Median viral load decrease was 0.48 [0.26–0.69] log₂ cycle threshold (ct) values, with no significant differences between SOTRs treated with monoclonal antibodies and those treated with antivirals. Viral load decrease was significantly associated with positive anti-s serology at baseline ($\beta$ = 0.196, p = 0.01), number of days between symptom onset and treatment ($\beta$ = 0.05, p = 0.03) and the number of comorbidities ($\beta$ = −0.05, p = 0.03). We provide evidence of real-world effectiveness of early therapy in SOTRs infected with SARS-CoV-2 and demonstrate the relevant role of humoral response to vaccination in enhancing early viral load decay during treatment. Full article

(This article belongs to the Topic Advances in Vaccines and Antimicrobial Therapy—2nd Edition)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-1